Serious infections in intensive care unit patients caused by multidrug-resistant (MDR) Klebsiella pneumoniae represent a major threat worldwide owing to increased mortality and limited treatment options. With the application of tigecycline for MDR pathogens, tigecycline-nonsusceptible K. pneumoniae isolates have recently emerged in China. To identify the susceptibility profile of MDR K. pneumoniae to tigecycline and evaluate the molecular characterization of tigecycline resistance, 214 MDR K. pneumoniae isolates were collected from blood samples of patients in intensive care units. MICs and clonal relatedness were determined by standard broth microdilution and multilocus sequence typing, respectively. Expression levels of efflux pumps and their global regulators were examined using real-time PCR. Mutations of local repressor were identified by PCR and sequencing. Our results show that the tigecycline resistance rate of 214 MDR K. pneumoniae isolates was 6.07 %. ST11 was the predominant clone type of tigecyclinenon-susceptible K. pneumoniae isolates. Expression of efflux pump AcrB and global regulator RamA correlated with tigecycline MICs (AcrB: x 2 =8.91, P=0.03; RamA: x 2 =13.91, P<0.01), and mean expression levels of AcrB for the MICs !4 mg l À1 were significantly higher than MICs 2 mg l À1 (t=2.48, P=0.029). In addition, one tigecycline-resistant isolate harboured a deletion mutation in the ramR gene. These data indicated a linear correlative trend for overexpression of the AcrB and the tigecycline MICs resulting from the upregulation of RamA. The emergence of molecular type ST11 of MDR K. pneumoniae isolates should be monitored to identify factors that contribute to tigecycline resistance in intensive care units.
INTRODUCTION
Klebsiella pneumoniae is one of the most common pathogenic bacteria in nosocomial and community-acquired infections that show resistance to b-lactams, aminoglycosides, quinolones and several other antibiotics (Henderson et al., 2013) . With the widespread application of broad-spectrum antibiotics, especially carbapenems, an increasing number of multidrug-resistant (MDR) K. pneumoniae strains are being isolated from hospitalized patients and community residents (Zhang et al., 2012) . Serious diseases such as bloodstream infections and liver abscesses caused by MDR K. pneumoniae, including carbapenemaseproducing K. pneumoniae, are clinically challenging, with increased mortality associated with these infections and limited treatment options (Munoz-Price et al., 2013; Tzouvelekis et al., 2012) .
Tigecycline, the first drug in the glycylcycline class of antibiotics, has broad-spectrum antibacterial activity against carbapenem-resistant Gram-negative bacteria and MDR pathogens. Tigecycline acts by binding to the ribosomal 30S subunit of bacteria and inhibiting the extension of amino acid chain, thus preventing synthesis of bacterial proteins. Tigecycline has few side effects, and its effectiveness does not vary with age, gender or the disease in patients (Jenner et al., 2013; Pankey, 2005) . Tigecycline has recently been approved for clinical use in China, following the rapid emergence of non-susceptible strains of different pathogens such as Acinetobacter baumannii (Mavroidi et al., 2015) , K. pneumoniae (He et al., 2015; Villa et al., 2014; Zhong et al., 2014) and other Enterobacteriaceae bacteria (Veleba et al., 2013) .
Previous studies have shown that susceptibility to tigecycline may decrease as a result of increased expression of efflux pumps of resistance-nodulation-cell division type in Enterobacteriaceae (Ruzin et al., 2005 (Ruzin et al., , 2008 . Among these pumps, the efflux pump AcrAB has been the most extensively studied in MDR K. pneumoniae. The expression of the AcrAB efflux pump is controlled by several AraC-type transcriptional regulators such as RamA, MarA, RarA and SoxS (Bratu et al., 2009; Ruzin et al., 2005; . Furthermore, Hentschke et al. (2010) and Ma et al. (1996) recently showed that the local repressors AcrR and RamR, acting through global stress signals, played a modulating role in the differential expression of acrAB genes and contributed to low-level tigecycline resistance in clinical Enterobacteriaceae isolates.
The oqxAB gene has been shown to encode an efflux pump conferring resistance to olaquindox, chloramphenicol and quinolones (Hansen et al., 2004 (Hansen et al., , 2007 Rodríguez-Martinez et al., 2013) . Moreover, recently showed that rarA upregulates, whereas oqxR downregulates, the expression of the OqxAB efflux pump system, which may also be a determining factor for tigecycline resistance. In addition, Nielsen et al. (2014) found an IS5 insertion element in tigecycline-non-susceptible strains and named it the KpgABC efflux pump. Overexpression of kpgABC genes in non-kpgABC K. pneumoniae increased the MIC of tigecycline fourfold, independently of the AcrAB and OqxAB efflux pumps that contribute to tigecycline resistance (Nielsen et al., 2014) .
The emergence of tigecycline resistance in MDR pathogens may involve several mechanisms. In this study, we obtained 214 clinical MDR K. pneumoniae isolates from blood samples of patients in three hospitals in two provinces of China and determined the tigecycline susceptibility of these isolates. The purpose of this study was to investigate the role of efflux pumps and their regulators in MDR K. pneumoniae isolates originating from China. Susceptibility testing. K. pneumoniae strains showing non-susceptibility to antibiotics in the VITEK-2 platform were tested further by the MIC method, with results interpreted according to the guidelines of the Clinical and Laboratory Standards Institute. MDR K. pneumoniae strains that were resistant to more than three kinds of antibiotics were selected for subsequent experiments. Two types of efflux pump inhibitors, namely, carbonyl cyanide-chlorophenylhydrazone (CCCP) and phenylalanine-arginine b-naphthylamide (PAbN), were used to test the efflux pump activities in MDR K. pneumoniae isolates. Susceptibility to tigecycline (Sigma-Aldrich), tigecycline with PAbN and tigecycline with CCCP was tested using the broth microdilution method (Table 1) . If the MICs decreased more than fourfold in the presence of efflux pump inhibitors, the inhibition effect was considered significant.
METHODS
Multilocus sequence typing. Multilocus sequence typing (MLST) assays were used to check the clonality of the MDR K. pneumoniae isolates. Seven housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB and tonB) were amplified, sequenced and then compared with sequences in the K. pneumoniae MLST database (http://www.pasteur.fr/recherche/ genopole/PF8/mlst/Kpneumoniae.html). Types are represented by circles, and the size of a circle indicates the number of strains in this particular type.
Quantitative real-time PCR. The expression levels of efflux pump components AcrAB, OqxAB and KpgABC and their transcriptional regulators RarA, RamA, MarA and SoxS were assessed using quantitative real-time PCR (qRT-PCR). The oligonucleotide primers used for realtime PCR are listed in Table 2 . Total bacterial RNA was extracted using a Total RNA Isolation Purification Extraction kit (Sangon). Then, RNA was reversed to cDNA using a PrimeScriptRT Reagent kit (TaKaRa) according to the manufacturer's instructions. The cDNAs were quantified by real-time PCR amplification using a SYBR Premix Ex Taq II kit (TaKaRa) on a Stratagene Mx3005P qPCR System (Agilent Technologies) with 40 cycles of 5 s at 95 C and 34 s at 60 C. Each sample was tested in triplicate. Expression levels of each target gene were normalized to that of a housekeeping gene (rrsE). Data were analysed using Agilent MxPro software based on the 2 À44Ct method. Relative expression levels of the mRNA were determined by comparison with expression levels in the reference strain K. pneumoniae ATCC 13883.
Detection of mutations of ramR, acrR and rpsJ and sequencing of PCR products. PCR and sequencing were performed to identify mutations in the acrR, ramR (local repressor) and rpsJ (ribosomal S10 protein) genes. For the analysis, gene fragments were directly sequenced and compared with the K. pneumoniae subsp. pneumoniae MGH 78578 reference sequence (CP000647). The primers designed for the PCR are listed in Table 2 .
Statistical analysis. A statistical analysis was performed using SPSS 17.0 software. The KruskalÀWallis test was used to determine the association between gene expression levels and drug resistance. The MIC 50 and MIC 90 values were subjected to descriptive statistical analysis. P<0.05 was considered significant.
RESULTS

Antimicrobial susceptibility testing and MLST
Of the 214 MDR K. pneumoniae isolates, 13 were not susceptible to tigecycline (MIC >2 mg l
À1
; non-susceptibility rate of 6.07 %). The tigecycline MIC distribution is presented in Fig. 1 . Four randomly selected tigecycline-susceptible reference strains and 13 tigecycline-non-susceptible K. pneumoniae were used for subsequent study of molecularresistance mechanisms. The susceptibility profiles of the 17 clinical MDR K. pneumoniae isolates against nine antimicrobial agents are shown in (Figs 2a and 3a) . For the isolates that overexpressed AcrB, we found that expression levels of MarA were elevated (1.37-29.98-fold; Fig. 3c ). Furthermore, high expression levels of pump KpgB (27.79-and 2.52-fold; Fig. 2d ) were observed in two non-susceptible isolates (K10 and K13).
Correlations between efflux pump expression and tigecycline MICs
The mean expression levels of efflux pumps and their regulators from different MIC groups are shown in Tables 3 and  4 . Based on the Kruskal-Wallis test, upregulation of the efflux pump AcrB and global regulator RamA correlated with tigecycline MICs (AcrB: x 2 =8.91, P=0.03; RamA: x 2 =13.91, P<0.01). In addition, results of this test indicated that mean expression levels of acrB for isolates with tigecycline MICs !4 mg l À1 were significantly different from isolates associated with MICs 2 mg l À1 (t=2.48, P=0.029, data not shown). The data showed a linear correlation between overexpression of the acrB gene and increased tigecycline and levofloxacin MICs caused by the upregulation of ramA (tigecycline: r s =0.694, P=0.002; and levofloxacin: r=0.555, P=0.021).
Efflux pump inhibition assays
To evaluate the role of efflux pumps in tigecycline resistance, an efflux pump inhibition assay was performed on 17 MDR K. pneumoniae isolates. Exposure of tigecycline-nonsusceptible isolates to efflux pump inhibitor PAbN resulted in a significant decrease in the MIC (2-8-fold), whereas MICs associated with susceptible isolates declined only slightly, from 1.125 to 0.875 mg l
À1
. CCCP caused a mean twofold decrease in the tigecycline MICs of non-susceptible strains. In contrast, there was no reduction in the MICs observed in susceptible strains under the same conditions ( Table 1) .
Mutations in the ramR gene and effect on tigecycline susceptibility
The presence of mutations in the ramR, acrR and rpsJ genes was determined by PCR and sequencing. Of the 17 MDR K. pneumoniae isolates, only one isolate (K1) harboured a deletion mutation in the sequence 'TGCGCTCGCTGA' in the ramR gene; this mutation led to an amino acid exchange in the repressor RamR. The MDR K. pneumoniae isolate K1 (MIC=32 mg l
À1
) harbouring the mutant ramR gene expressed a high level of ramA (35.62-fold). Mutations in the acrR and rpsJ genes were not detected in the 17 MDR K. pneumoniae isolates.
DISCUSSION
Nosocomial infections caused by MDR and extensively drug-resistant Gram-negative bacteria, both of which carry a variety of resistant determinants, are becoming a significantly worldwide problem (Karaiskos & Giamarellou, 2014; Magiorakos et al., 2012; Zhou et al., 2015) . MDR and extensively drug-resistant bacteria can cause several serious infections that are associated with increased mortality because treatment options are limited. Specifically, carbapenemaseproducing MDR K. pneumoniae are associated with a mortality rate of 23-75 %, and many strains show resistance to most broad-spectrum antibiotics, including cephalosporins, carbapenems and colistin (He et al., 2015; Tzouvelekis et al., 2012) .
Tigecyclines have been shown to cure severe intra-abdominal infections, skin and skin structure infections and community-acquired pneumonia, with approval from the US Food and Drug Administration since 2005. Recently, they have been used off-label as an antibiotic for MDR bacteria. At the early stage of tigecycline use, the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) study by Denys et al. (2013) , conducted between 2005 and 2011, showed that the MIC 50 and MIC 90 of K. pneumoniae producing extendedspectrum b-lactamases were 0.25 and 0.5 mg l
À1
, respectively. However, with widespread use in clinical practice, the sensitivity to tigecycline has decreased in MDR K. pneumoniae. In the 214 MDR K. pneumoniae isolates that were obtained from blood samples of patients in ICUs in northern China, the tigecycline resistance rate was 6.07 % (13/ 214), although this number might change with an increase in the number of samples tested. However, there was the possibility that the predominant clonal type complex factor (ST11) may contributed to tigecycline non-susceptibility as a selection bias among these isolates.
Seventeen MDR K. pneumoniae isolates that were collected from three hospitals in two cities belong to two STs. ST11 was found to be the dominant ST (16/17; 94.12 %). ST11 is the most common KPC-producing K. pneumoniae ST in China and some other regions, with only one single-locus variant found in ST258 (Giakkoupi et al., 2011; Li et al., 2014; Pereira et al., 2013) . ST11 may have the potential to disseminate widely. Therefore, the ST11 clone from K. pneumoniae isolates should be investigated to identify potential factors for tigecycline resistance. Many resistance mechanisms in other clinically relevant bacterial species have been described. The most common mechanism for tigecycline resistance is the efflux pump of resistancenodulation-cell division type in Enterobacteriaceae. Our results support the hypothesis that AcrB expression levels correlate with tigecycline MICs in MDR K. pneumoniae and that overexpression of the acrB gene was caused by the upregulation of ramA. In contrast with previous reports, the global regulators MarA and SoxS did not show a correlation between the expression of the RamA and tigecycline MICs (Bratu et al., 2009) . Some MDR K. pneumoniae strains in our study, such as isolates K6, K9, K10, K14 and K16, expressed high levels of OqxB. The expression levels of OqxB and its transcription regulator RarA were elevated; however, there was no obvious correlation with tigecycline MICs. These results implied that other genetic regulative mechanisms of upregulated efflux pumps might be involved in regulation of gene expression and response to the bacteria exposed to antibiotics (Howden et al., 2013) . Nielsen et al. (2014) postulated that insertion of the IS5 integron might contribute to the increased expression levels AcrB fold expression change
KpgA fold expression change OqxB fold expression change of KpgABC in K. pneumoniae, leading to decreased sensitivity to tigecycline. We found that KpgB expression levels increased 27.79-fold only in K10; however, there was no difference in tigecycline MICs associated with this increase in the 17 MDR isolates in our study. We will obtain additional MDR K. pneumoniae isolates for analysis, and we will evaluate whether the IS5 insertion influences KpgABC expression in future studies.
Decreased sensitivity to tigecycline may be associated with a variety of drug resistance mechanisms, including cross-drug resistance determinants. To confirm the effect of efflux pumps on resistance to tigecycline, we exposed non-susceptible isolates to efflux pump inhibitors and observed a significant decrease in MICs relative to those of susceptible isolates. These data suggest that efflux pumps may be related to decreased susceptibility to tigecycline. Of the 17 MDR K. pneumoniae isolates, only one isolate harboured a deletion mutation in the sequence 'TGCGCTCGCTGA' in ramR, and no mutations in the acrR and rpsJ genes were found. A previous study suggested that transformation of one mutant with wild-type ramR could restore susceptibility to tigecycline and repress overexpression of acrB (He et al., 2015) . However, not all mutations in the ramR gene contribute to resistance to tigecycline. The relationship between the deletion mutation in the ramR gene and the development of tigecycline resistance will need to be elucidated in further studies.
Our study had several limitations, including the small number of tigecycline-non-susceptible K. pneumoniae isolates obtained from a single ICU. Nevertheless, differential gene expression of efflux pumps and their regulators was found in MDR K. pneumoniae from blood samples of patients in RarA fold expression change ICUs in the present study. In tigecycline-non-susceptible clinical isolates of K. pneumoniae, RamA plays a major role in the upregulated expression of the AcrAB efflux pump, contributing to decreased susceptibility to tigecycline and high levels of resistance to levofloxacin. Given the propensity of Klebsiella to develop cross-resistance, exposure to sub-therapeutic concentrations of antibiotics for long periods may promote the rapid emergence of tigecycline resistance. Finally, the emergence of molecular type ST11 of MDR K. pneumoniae isolates should be monitored to identify factors that contribute to tigecycline resistance in ICUs.
